Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...

Grade 3-4 treatment-related adverse events occurred in 14% and 36% of patients, respectively. Despite the activity observed with nivolumab and ipilimumab in this exploratory analysis the higher rate ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

NP-101 plus nivolumab and ipilimumab demonstrated activity in patients with metastatic EP-NECs that were refractory to chemotherapy.

"These results represent the longest follow-up in a phase III trial of checkpoint inhibitor combination therapy in first-line advanced RCC and continue to support nivolumab/ipilimumab as standard ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...

Nivolumab plus ipilimumab shows promising real-world effectiveness in intermediate- or poor-risk mRCC, with median overall survival of 38.4 months and progression-free survival of 11.1 months.

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

Researchers compare nivolumab as monotherapy or in combination with chemotherapy vs conventional treatment on overall survival and progression-free survival in patients with advanced unresectable ...